FISCHER · Fischer Medical Ventures Ltd · Chemical Manufacturing
FISCHER · Fischer Medical Ventures Ltd · Chemical Manufacturing
As of 05 Nov close
52-week range
79.4% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹82 Cr
Revenue YoY
PAT YoY
-22.0%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
5.9
P/S (TTM)
6.8
Sector P/E
Not available from data source
Dividend yield
+0.1%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| FISCHER (this stock) | 89 | 5.9 | +8.4% | +8.1% | 0.28 | +0.1% |
| Asian Paints | 53 | 11.1 | +12.8% | +22.3% | 0.18 | +1.1% |
| Solar Industries India | 99.6 | 26.6 | +17.6% | +31.4% | 13.68 | +0.1% |
| Pidilite Industries | 61.3 | 19.4 | +17.2% | +24.4% | 0.04 | +0.7% |
Promoter
rising 1q
FII
rising 3q
MF
Not available from data source
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 17 Aug 2026 | FMV Holdings Pte Ltd | BUY | 4,54,210 | ₹1.06 Cr |
| 14 Aug 2026 | Shankar Varadharajan | BUY | 60,00,000 | ₹14.04 Cr |
| 14 Aug 2026 | FMV Holdings Pte Ltd | BUY | 73,35,909 | ₹17.17 Cr |
| 13 Aug 2026 | Shankar Varadharajan | BUY | 15,00,000 | ₹3.51 Cr |
| 13 Aug 2026 | FMV Holdings Pte Ltd | BUY | 97,78,217 | ₹22.88 Cr |
| 12 Aug 2026 | Shankar Varadharajan | BUY | 12,00,000 | ₹2.81 Cr |
| 12 Aug 2026 | FMV Holdings Pte Ltd | BUY | 54,31,664 | ₹12.71 Cr |
| 11 Aug 2026 | Shankar Varadharajan | BUY | 23,00,000 | ₹5.38 Cr |
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-09-22 | FISCHER | 6741907 | 2 | STRONG | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedFischer Medical Ventures Limited (FISCHER) outlines its Next Phase of Innovation-Led Growth, focusing on scaling its healthcare technology solutions, expanding its imaging portfolio, and entering new markets. The company emphasizes its commitment to making advanced healthcare more accessible through indigenous technologies and AI-enabled diagnostics. It highlights opportunities in expanding its Spincare business, strengthening intraoperative imaging, and extending its AI-driven preventive healthcare ecosystem. The report also mentions the importance of India's growing healthcare infrastructure and favorable policy environment in supporting its growth.
- Scaling healthcare solutions through innovation and expansion of imaging portfolio
- Focus on AI-enabled diagnostics and preventive healthcare ecosystems
- Expanding into new markets and strengthening manufacturing capabilities
- Leveraging India's healthcare infrastructure and policy environment
Key takeaway: Fischer Medical Ventures is focused on scaling its innovation-led growth through expansion of its healthcare technology solutions, leveraging India's healthcare infrastructure and policy environment to make advanced healthcare more accessible.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Default / Covenant Breach
1 occurrenceRecent (last 12 months)
The company obtained a loan of ₹11.62 Lakhs from its subsidiary, Time Medical International Ventures (India) Private Limited, during the year.
Routine disclosures
Related-Party Transaction
1 occurrenceRecent (last 12 months)
The company submitted the half-yearly disclosure of related party transactions for the period ended 30th September, 2025 with a delay of a few minutes, leading to fines levied by the Stock Exchanges under SEBI's Standard Operating Procedure.
Management & Board Governance
1 occurrenceRecent (last 12 months)
Independent Director Sanjay Jayantilal Jain resigned on 14-08-2026. Independent Directors Jacob Thomas and Roberto M Pagdanganan resigned on 14-08-2025.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
9.35% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).